

Press Release

MediGene to Present Recent Data Obtained in a Clinical Trial of Oncolytic Virus NV1020 on the Occasion of the ASCO GI Symposium

Martinsried/Munich, January 25, 2008. MediGene AG announced today that recent data obtained in the ongoing trial of oncolytic virus (NV1020) will be presented on a poster on the occasion of the ASCO Gastrointestinal Cancers (GI) Symposium which takes place in Orlando, Florida on January 25, 2008. The principal investigator of this trial, Tony Reid, M.D., Ph.D. at the University of California San Diego, will present data about the overall survival rate of the patients obtained in the phase I part of the trial as well as new safety data.

The phase I/II trial of NV1020 for the treatment of liver metastases in patients suffering from colorectal carcinoma is currently being conducted at seven major oncological centers in the USA. In June 2007, MediGene reported positive safety data and efficacy trends. Patient recruitment for the phase II part of the trial was completed in September 2007, the final analysis of the trial is expected this year.

Dr. Peter Heinrich, Chief Executive Officer of MediGene AG, comments: "We have repeatedly been able to report encouragingly positive safety data as well as efficacy trends shown in this trial. The fact that our report was chosen for presentation at the renowned ASCO GI Symposium underlines again that there is a vivid interest in our oncolytic viruses on the part of the scientific community."

NV1020: MediGene's oncolytic herpes simplex virus (oHSV) NV1020 is designed to selectively multiply in tumor cells, thus destroying the tumor (oncolysis). The technology is based on the assumption that oHSV function more specifically and efficiently than conventional cancer therapies do, without causing serious adverse events. They could provide a therapeutic alternative against tumors that are inoperable or have developed a resistance to chemotherapy or radiotherapy. Moreover, the combination of oHSV and established standard therapies such as chemotherapy or radiotherapy may create a synergistic effect.

Trial design: The CT 1030 trial is composed of a dose-finding part which was completed in 2006, followed by a phase II part to investigate tolerability and efficacy of the optimum dose of NV1020. The patients participating are suffering from a colorectal adenocarcinoma which has metastasized. They are treated with four injections of NV1020, followed by an approved standard chemotherapy. This treatment is administered at renowned oncological centers at seven leading American universities, i.e. Vanderbilt University, Nashville; Mary Crowley Medical Research Center (MCMRC), Dallas; Mayo Clinic Medical School, Rochester; Harvard Medical School, Boston; Memorial Sloan Kettering Cancer Center (MSKCC), New York; University of California San Diego (UCSD), and University of Pittsburgh Liver Cancer Center.

Presentations of the ongoing trial CT1030 were held at the following congresses:

- ILCA 2007, October 05-07, 2007, Barcelona, Spain
- ESMO 2007, July 05-08, 2007, Lugano, Switzerland
- ASCO GI Cancer Meeting, January 19-21, 2007, Orlando, FL., USA
- DDW 2006, May 2006, Los Angeles, CA., USA



This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of MediGene as of the date of this release. These forward-looking statements are no guarantees for future performance, and the forward-looking events discussed in this press release may not occur. MediGene disclaims any intent or obligation to update any of these forward-looking statements. MediGeneTM is a trademark of MediGene AG.

MediGene AG is a publicly quoted (Frankfurt, Prime Standard: MDG) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company to have drugs on the market. In 2008, the company plans to start its own sales activities in select European countries. MediGene's drug pipeline includes several products in clinical development, among them two drug candidates with an estimated revenue potential of more than one billion Euro. In addition, MediGene is active in various research projects and possesses platform technologies for developing active compounds.

Contact MediGene AG:

Julia Hofmann/Dr. Georg Dönges, Public Relations
Dr. Michael Nettersheim, Investor Relations

Email: investor@medigene.com
Fax: ++49 - 89 - 85 65 - 2920
Tel.: ++49 - 89 - 85 65 - 3317
Tel.: ++49 - 89 - 85 65 - 2946